FDA's Fast-Track for Rexulti Raises Concerns
Por um escritor misterioso
Descrição
CMS efforts to reduce use of unnecessary antipsychotics in nursing homes may conflict with marketing efforts for the drug.
FDA's Fast Track Approval Coronavirus Treatment Acceleration Program
Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America
Inline XBRL Viewer
Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America
Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America
FDA-Approved Drugs to Treat Schizophrenia Journal of Psychosocial Nursing and Mental Health Services
FDA rushes approval of dementia drug that quadruples risk of death
Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America
FDA fast-tracks drug for dementia agitation that increases risk of death 4 times - Study Finds
Accelerated Change: Understanding the FDA's Expedited Pathways
Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America
FDA fast-tracks drug for dementia agitation that increases risk of death 4 times - Study Finds
FDA's accelerated drug approvals often lack confirmatory evidence : Shots - Health News : NPR